» Articles » PMID: 37409224

Prevalence and Associated Factors of Metabolic-associated Fatty Liver Disease in Overweight Finnish Children and Adolescents

Overview
Specialty Endocrinology
Date 2023 Jul 6
PMID 37409224
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Data on the prevalence of pediatric fatty liver disease remain limited, partly due to challenges in diagnosis. A novel concept of metabolic-associated fatty liver disease (MAFLD) makes it possible to establish the diagnosis in overweight children with sufficiently elevated alanine aminotransferase (ALT). We investigated the prevalence, risk factors, and metabolic co-morbidities of MAFLD in a large group of overweight children.

Methods: Data on 703 patients aged 2-16 years examined due to overweight in different levels of healthcare in 2002-2020 were collected retrospectively from patient records. MAFLD was here defined as ALT >2x reference (>44 U/l in girls and >50 U/l in boys) in overweight children according to recently updated definition. Patients with MAFLD and without it were compared, and subgroup analyses were conducted among boys and girls.

Results: Median age was 11.5 years, and 43% were girls. Altogether 11% were overweight, 42% obese and 47% severely obese. Abnormal glucose metabolism was present in 44%, dyslipidemia in 51%, hypertension in 48% and type 2 diabetes (T2D) in 2%. MAFLD prevalence varied between 14-20% in examined years without significant change (p=0.878). The pooled prevalence over the years was 15% (boys 18%, girls 11%; p=0.018), peaking in girls at early puberty and increasing in boys with age and puberty. Associated factors in boys were T2D (OR 7.55, 95% CI 1.23-46.2), postpubertal stage (5.39, 2.26-12.8), increased fasting insulin (3.20, 1.44-7.10), hypertriglyceridemia (2.97, 1.67-5.30), hyperglycemia (2.88, 1.64-5.07), decreased high-density lipoprotein (HDL) cholesterol (2.16, 1.18-3.99), older age (1.28, 1.15-1.42) and higher body-mass-index (1.01, 1.05-1.15), and in girls T2D (18.1, 3.16-103), hypertriglyceridemia (4.28, 1.99-9.21), and decreased HDL (4.06, 1.87-8.79).

Conclusion: Prevalence of MAFLD was 15%, with no statistically significant increase in the 2000s. The condition was associated in general with male gender, puberty stage and disturbances in glucose and lipid metabolism, and higher age and BMI in boys.

Citing Articles

Impact of segmental body composition on metabolic fatty liver disease in Chinese children.

Hu M, Sun D, Yang F, Zheng X, Wu N, Zhang H Front Endocrinol (Lausanne). 2025; 16:1505050.

PMID: 40034234 PMC: 11872705. DOI: 10.3389/fendo.2025.1505050.


Fructose Intake and Unhealthy Eating Habits Are Associated with MASLD in Pediatric Obesity: A Cross-Sectional Pilot Study.

Faienza M, Baima J, Cecere V, Monteduro M, Farella I, Vitale R Nutrients. 2025; 17(4).

PMID: 40004960 PMC: 11858415. DOI: 10.3390/nu17040631.


Web of Science-Based Visualization of Metabolic Dysfunction-Associated Fatty Liver Disease in Pediatric and Adolescent Populations: A Bibliometric Study.

Hu L, Du H, Zhou Q, Liu C, Zhang T, Yuan M Health Sci Rep. 2025; 8(2):e70409.

PMID: 39897463 PMC: 11779742. DOI: 10.1002/hsr2.70409.


Potential alternative and novel biomarkers for paediatric MAFLD: exploratory evidence from a Chinese cohort.

Yang F, Hu M, Xu L, Zheng X, Zhu L, Zhang L BMC Gastroenterol. 2025; 25(1):28.

PMID: 39844086 PMC: 11752933. DOI: 10.1186/s12876-025-03619-2.


Converging Pathways between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Diabetes in Children.

Faienza M, Farella I, Khalil M, Portincasa P Int J Mol Sci. 2024; 25(18).

PMID: 39337412 PMC: 11432101. DOI: 10.3390/ijms25189924.


References
1.
Schwimmer J, Pardee P, Lavine J, Blumkin A, Cook S . Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008; 118(3):277-83. PMC: 2996820. DOI: 10.1161/CIRCULATIONAHA.107.739920. View

2.
Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P . Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021; 6(10):864-873. DOI: 10.1016/S2468-1253(21)00183-7. View

3.
Flynn J, Kaelber D, Baker-Smith C, Blowey D, Carroll A, Daniels S . Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017; 140(3). DOI: 10.1542/peds.2017-1904. View

4.
Marshall W, Tanner J . Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970; 45(239):13-23. PMC: 2020414. DOI: 10.1136/adc.45.239.13. View

5.
Schwimmer J, Deutsch R, Kahen T, Lavine J, Stanley C, Behling C . Prevalence of fatty liver in children and adolescents. Pediatrics. 2006; 118(4):1388-93. DOI: 10.1542/peds.2006-1212. View